Molecular Docking, Synthesis and Biological Evaluation of Sulphonylureas/ Guanidine Derivatives as Promising Antidiabetic Agent

Author(s): Ishan I. Panchal*, Dhrubo Jyoti Sen, Ashish D. Patel, Umang Shah, Mehul Patel, Archana Navale, Vashisth Bhavsar

Journal Name: Current Drug Discovery Technologies

Volume 15 , Issue 4 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: A series of novel sulphonylureas/guanidine derivatives was designed, synthesized, and evaluated for the treatment of diabetes mellitus. In this study, the designed compounds were docked with AKR1C1 complexes by using glide docking program and docking calculations were performed to predict the binding affinity of the designed compounds with the binding pocket of protein 4YVP and QikProp program was used to predict the ADME/T properties of the analogues.

Methods: All the targeted derivatives were synthesized and purified by recrystallization. Synthesized compounds were characterized by various physicochemical and various spectroscopic techniques like melting point, thin layer chromatography, infrared spectroscopy (KBr pellets), mass spectroscopy(m/z), 1H NMR (DMSO-d6), and 13C NMR. The synthesized compounds were further studied for biological evolution by alloxan (150 mg/dl, intraperitonial) induced diabetic rat model for in-vivo studies.

Result: Among all the synthesized derivatives, 5c and 5d were most potent as per binding energy. Compound 5i have shown a better plasma glucose reduction compared to glibenclamide. Hence, it will be further used as a lead compound to develop a more such kind of agent.

Conclusion: The docking study revealed that in all designed sulphonylureas/ guanidine series of compounds 5c and 5d were found to be most potent compounds as per the binding energy compared to glibenclamide. With the help of detailed study of in vivo biological activity, we observed that compound 5i gives better result compared to glibenclamide as standard.

Keywords: Diabetes mellitus, sulphonylureas, AKR1C1, QikProp, alloxan, antidiabetic agent.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 03 September, 2018
Page: [315 - 325]
Pages: 11
DOI: 10.2174/1570163814666171002102904
Price: $65

Article Metrics

PDF: 43